RNAZ Stock Price, TransCode Therapeutics, . Quote, Chart

Market Summary

USD1.15+0.27

Delayed

30.68%

RNAZ Stock Price

View Fullscreen

RNAZ RSI Chart

RNAZ Valuation

Market Cap

7.6M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

8.25

Price/Free Cashflow

-0.43

RNAZ Price/Sales (Trailing)

RNAZ Profitability

Return on Equity

-371.47%

Return on Assets

-233.58%

Free Cashflow Yield

-230.3%

RNAZ Fundamentals

RNAZ Revenue

Revenue (TTM)

923.0K

Rev. Growth (Yr)

-92.9%

Rev. Growth (Qtr)

-48.9%

RNAZ Earnings

Earnings (TTM)

-17.0M

Earnings Growth (Yr)

31.49%

Earnings Growth (Qtr)

19.27%

Breaking Down RNAZ Revenue

Last 7 days

-19.1%

Last 30 days

128%

Last 90 days

67.7%

Trailing 12 Months

-99.5%

How does RNAZ drawdown profile look like?

RNAZ Financial Health

Current Ratio

2.48

RNAZ Investor Care

Shares Dilution (1Y)

31065.29%

Diluted EPS (TTM)

97.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.0M	0	975.5K	923.0K
2022	0	545.7K	813.1K	1.1M
2021	0	0	0	278.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of TransCode Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 28, 2023	dudley robert michael	bought	49,980	0.51	98,000	chief executive officer
Sep 28, 2023	fitzgerald thomas a	bought	25,168	0.51	49,350	chief financial officer
Jun 21, 2023	dudley robert michael	bought	31,818	2.6515	12,000	chief executive officer
Jun 20, 2023	dudley robert michael	bought	16,846	2.5498	6,607	chief executive officer
Jun 09, 2023	dudley robert michael	bought	52,440	2.76	19,000	chief executive officer
Sep 14, 2022	dudley robert michael	bought	23,000	1.15	20,000	chief executive officer
Jun 16, 2022	fitzgerald thomas a	bought	15,240	1.27	12,000	chief financial officer
May 31, 2022	dudley robert michael	bought	3,739	1.8699	2,000	chief executive officer
May 27, 2022	dudley robert michael	bought	51,643	1.8444	28,000	chief executive officer

Which funds bought or sold RNAZ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-266	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	228,684,000	228,684,000	0.13%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-909	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	3,365	3,365	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-8,240	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	15,009	15,009	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-46,458	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-8,607	-	-%

Are Funds Buying or Selling RNAZ?

Are funds buying RNAZ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RNAZ

No. of Funds

Unveiling TransCode Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 15, 2024	medarova zdravka	0.4%	112,077	SC 13G/A
Feb 14, 2024	tang capital partners lp	0.0%	0	SC 13G/A
Feb 13, 2024	lind global fund ii lp	0.1%	26,279	SC 13G/A
Dec 07, 2023	lind global fund ii lp	9.9%	2,500,000	SC 13G
Oct 10, 2023	dudley robert michael	1.9%	227,743	SC 13D/A
Sep 26, 2023	tang capital partners lp	9.99%	354,700	SC 13G
Jun 16, 2023	dudley robert michael	6.0%	111,534	SC 13D/A
Feb 10, 2023	medarova zdravka	12.7%	1,660,739	SC 13G/A
Dec 20, 2022	dudley robert michael	12.7%	1,756,516	SC 13D
Dec 20, 2022	dudley robert michael	10.6%	1,433,369	SC 13G

Recent SEC filings of TransCode Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 13, 2024	DEFA14A	DEFA14A
May 10, 2024	PRE 14A	PRE 14A
May 10, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 23, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report

Peers (Alternatives to TransCode Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

TransCode Therapeutics, Inc. News

Latest updates

TransCode Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2
Revenue	-100.0%	-	27.00	53.00	79.00	384	655	447	239	32.00	57.00
Operating Expenses	-19.0%	3,289	4,059	5,328	4,901	5,495	4,954	4,707	2,986	2,360	356
S&GA Expenses	-100.0%	-	695	1,985	2,310	2,809	1,910	2,087	1,701	1,367	144
R&D Expenses	-47.7%	1,759	3,364	3,343	2,591	2,687	3,044	2,620	1,286	993	212
EBITDA Margin	-	-	-	-	9.74*	10.38*	12.73*	16.44*	40.32*	63.36*	50.50*
Interest Expenses	-84.0%	6.00	35.00	11.00	8.00	11.00	15.00	704*	0.50*	333*	42.00
Income Taxes	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-	-	-	-	9.61*	10.26*	12.60*	16.31*	39.82*	62.42*	48.57*
Net Income	19.3%	-3,300	-4,087	-5,299	-4,816	-5,134	-4,289	-4,671	-2,799	-2,329	2,771
Net Income Margin	8.2%	-18.45*	-20.09*	-20.08*	-18.40*	-16.26*	-18.73*	-24.32*	-24.59*	-	-
Free Cashflow	30.5%	-3,941	-5,674	-3,504	-4,512	-4,047	-4,422	-3,414	-1,686	-3,139	-98.24

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	41.0%	7,290	5,170	10,228	5,882	5,591	7,588	12,016	14,155	18,850	22,938	25,360	1,522	1,055
Current Assets	50.7%	6,714	4,455	9,373	4,893	4,347	7,379	11,570	13,921	18,635	22,732	25,204	540	831
Cash Equivalents	75.5%	4,914	2,800	7,453	3,572	1,600	4,968	8,791	13,438	16,853	20,826	22,500	80.00	828
Net PPE	-23.5%	92.00	121	152	179	192	209	210	235	215	206	156	92.00	-
Liabilities	-23.3%	2,706	3,529	5,788	3,789	5,827	4,347	3,771	1,727	1,849	2,534	2,205	6,558	4,464
Current Liabilities	-22.5%	2,706	3,491	5,598	3,523	5,449	4,347	3,771	1,727	1,849	2,534	2,205	1,533	405
Shareholder's Equity	179.4%	4,584	1,641	4,440	2,092	-236	3,241	8,244	12,428	17,001	20,404	23,155	-	-
Retained Earnings	-7.1%	-49,700	-46,400	-42,300	-37,000	-32,700	-27,870	-22,736	-18,446	-13,800	-10,305	-7,506	-5,176	-3,461
Additional Paid-In Capital	13.0%	54,327	48,057	46,768	39,121	32,449	31,111	30,979	30,873	30,775	30,708	30,669	149	66.00
Shares Outstanding	825.7%	5,808	627	267	49.00	20.00	16.00	16.00	16.00	16.00	211	14.00	6.00	6.00
Float	-	-	-	-	4,400	-	-	-	11,000	-	-	-	32,531	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	30.6%	-3,937	-5,674	-3,500	-4,400	-4,500	-4,019	-4,422	-3,372	-3,948	-1,600	-3,067	-76.00	-522	-	-	-
Share Based Compensation	-41.0%	183	310	392	175	159	131	106	99.00	61.00	39.00	64.00	35.00	48.00	-	-	-
Cashflow From Investing	-Infinity%	-3.84	-	-4.61	-18.11	-12.90	-28.21	-	-42.05	-30.66	-82.73	-71.55	-22.24	-75.30	-	-	-
Cashflow From Financing	522.3%	6,087	978	7,391	6,360	1,181	226	-225	-	6.00	9.00	25,560	79.00	-131	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RNAZ Income Statement

2024-03-31

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 1,759,020	$ 2,591,350
General and administrative	1,529,962	2,296,334
Total operating expenses	3,288,982	4,887,684
Operating loss	(3,288,982)	(4,887,684)
Other income (expense)
Grant income	27,057	79,409
Currency exchange gain/(loss)	(55,349)
Interest income	168	4,770
Interest expense	(9,706)	(13,429)
Total other income (expense)	(37,830)	70,750
Net loss	$ (3,326,812)	$ (4,816,934)
Weighted-average common shares outstanding, Basic	5,142,398	18,593
Weighted-average common shares outstanding, Diluted	5,142,398	18,593
Net loss per share, Basic	$ (0.65)	$ (259.07)
Net loss per share, Diluted	$ (0.65)	$ (259.07)

RNAZ Balance Sheet

2024-03-31

BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 4,913,676	$ 2,767,598
Prepaid expenses and other current assets	1,800,346	1,687,846
Total current assets	6,714,022	4,455,444
Property and equipment, net of depreciation	92,379	120,707
Right-of-use asset, net of amortization	372,210	481,694
Security deposit	111,856	111,856
Total assets	7,290,467	5,169,701
Current liabilities:
Accounts payable and accrued expenses	2,366,764	3,051,259
Deferred grant income	0	27,057
Short-term lease liability	339,408	412,280
Total current liabilities	2,706,172	3,490,596
Long-term lease liability		38,291
Total liabilities	2,706,172	3,528,887
Stockholders' equity:
Preferred stock - $0.0001 par value; 10,000,000 shares authorized at March 31, 2024, and December 31, 2023; -0- shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock - $0.0001 par value, 290,000,000 shares authorized at March 31, 2024, and December 31, 2023; 5,808,053 and 627,448 shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively	581	63
Additional paid-in capital	54,326,870	48,057,095
Accumulated deficit	(49,743,156)	(46,416,344)
Total stockholders' equity	4,584,295	1,640,814
Total liabilities and stockholders' equity	$ 7,290,467	$ 5,169,701

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

CEO	Mr. Robert Michael Dudley
WEBSITE	transcodetherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	19

TransCode Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for TransCode Therapeutics, Inc.? What does RNAZ stand for in stocks?

RNAZ is the stock ticker symbol of TransCode Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TransCode Therapeutics, Inc. (RNAZ)?

As of Fri May 17 2024, market cap of TransCode Therapeutics, Inc. is 7.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNAZ stock?

You can check RNAZ's fair value in chart for subscribers.

What is the fair value of RNAZ stock?

You can check RNAZ's fair value in chart for subscribers. The fair value of TransCode Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TransCode Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RNAZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TransCode Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether RNAZ is over valued or under valued. Whether TransCode Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact TransCode Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNAZ.

What is TransCode Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RNAZ's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 8.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNAZ PE ratio will change depending on the future growth rate expectations of investors.